Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea

Objective. To investigate the effectiveness and safety of pembrolizumab and lenvatinib (PEMBRO+LEN) for recurrent endometrial cancer (EC) in a real-world setting. Methods. This multicenter retrospective cohort study included patients with recurrent EC who received PEMBRO+LEN between March 2020 andMay 2021 at three tertiary hospitals in Korea. We summarized patient characteristics and evaluated the response rates, survival outcomes, and treatment-related adverse events (AEs). Results. In total, 48 patients were included in the study. The median age of the patients was 62.5 (range, 42-78) years. The most common histologic subtypewas endometrioid adenocarcinoma (43.8%), followed by serous adenocarcinoma (25.0%). Most patients (91.7%) had mismatch repair-proficient tumors. Patients received PEMBRO+LEN for a median of 4.5 cycles, during which the best objective response rate and disease control rate were 23.8% (95% CI, 11.9-38.1) and 76.2% (95% CI, 61.9-88.1), respectively. Overall, 56.2% of patients experienced LEN dose reduction once ormore and 16.7% experienced LEN interruption. Themost common treatmentrelated AEs were fatigue (18.8%), hypertension (16.7%), and hypothyroidism (14.6%). Total of 8 patients (16.7%) discontinued LEN during the treatment because of treatment-related AEs. Serum CA-125 level was the only prognostic factor for progression-free survival (adjusted hazard ratio, 4.41; 95% confidence interval, 1.19-16.36; p = 0.03). Conclusions. In our real-world study, Korean patientswith recurrent ECwho received PEMBRO+LEN showed lower treatment response rate and similar treatment discontinuation rate, compared to clinical trials. (C) 2022 Elsevier Inc. All rights reserved.

Automated summary

This study investigated the effectiveness and safety of pembrolizumab and lenvatinib for recurrent endometrial cancer in a real-world setting. The results showed lower treatment response rate and similar treatment discontinuation rate compared to clinical trials.